Company intelligence / Profile preview

Symphony Medical

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Symphony Medical was a clinical-stage biotechnology company dedicated to developing biological treatments for cardiovascular disorders, with a primary focus on atrial fibrillation (AF). The company's proprietary technology involved the use of biopolymers and biological agents to modify cardiac electrical conduction, providing a less invasive alternative to traditional catheter ablation. Its lead candidate was designed to treat AF by slowing the heart's ventricular response. In 2006, the company was acquired by Boston Scientific to enhance its cardiac rhythm management and electrophysiology offerings.

Therapeutic areas: Cardiovascular
Modalities: BiologicHydrogel-based drug delivery therapy
Industry: Biotech

Partnerships

Boston Scientific

Beyond the preview

Go deeper on Symphony Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symphony Medical.

Explore the full profile